Back to search

Peptide record

TPDB10474

Antibacterial Antifungal Hemolysis Toxicity standard
24 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10474
Antibacterial Antifungal Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia CAFPdb dbAMP PD_Hemolysis
standard
No
A 24-aa standard-residue multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CAFPdb, and other sources, with an available 3D structural model.
Sequence
FLPLIAGLAAKFLPKIFCAITKKC
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C127H208N28O26S2
RNDEQHMSWYV
ALK
2607.34
10.17
4
0
14
+4
-1.22
1.225
130.42
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
125
0.05
3
Residue Composition
number
4
A
0
R
0
N
0
D
2
C
0
E
0
Q
1
G
0
H
3
I
4
L
4
K
0
M
3
F
2
P
0
S
1
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 4 R: 0 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 4 K: 4 M: 0 F: 3 P: 2 S: 0 T: 1 W: 0 Y: 0 V: 0
Chemical Descriptors
24 reviewed residue count
C127H208N28O26S2 sequence-only estimate (linear, free termini)
2607.34 sequence-only estimate (linear, free termini)
10.17 sequence-only estimate (linear, free termini)
+4 sequence-only estimate (linear, free termini)
-1.22 sequence-only estimate (linear, free termini)
1.225 sequence-only estimate (linear, free termini)
Evidence Records 2 records
Evidence 1 Activity

Activity

10% Hemolysis
Toxicity
1.576 µM
Hemolytic Cytotoxic
10% Hemolysis | 1.576 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Modification and Targeted Design of N-Terminal Truncates Derived from Brevinin with Improved Therapeutic Efficacy | Biology (Basel) | 2020
Evidence 2 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis